Sulfanyltriazole/tetrazoles: a promising class of HIV-1 NNRTIs

Mini Rev Med Chem. 2009 Jul;9(8):1014-23. doi: 10.2174/138955709788681618.


There is an urgent need for the design and development of new and safer drugs for the treatment of human immunodeficiency virus (HIV) infection, specifically active against drug-resistant viral strains. Recently, sulfanyltriazole/tetrazole derivatives were reported as potent HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs), with low nanomolar intrinsic activity against RT and submicromolar antiviral activity in HIV infected cells. In this review, the structural modifications, SAR analysis and docking studies of sulfanyltriazole/tetrazoles HIV-1 NNRTIs are discussed, and other interesting NNRTIs with the same or similar pharmacophore as the sulfanyltriazole/tetrazole derivatives are also presented and analyzed for their in SAR.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-HIV Agents / chemistry*
  • Anti-HIV Agents / pharmacology
  • Anti-HIV Agents / therapeutic use*
  • HIV Infections / drug therapy*
  • HIV-1 / drug effects
  • Humans
  • Models, Molecular
  • Reverse Transcriptase Inhibitors / chemistry*
  • Reverse Transcriptase Inhibitors / pharmacology
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Structure-Activity Relationship
  • Tetrazoles / chemistry
  • Tetrazoles / pharmacology
  • Tetrazoles / therapeutic use*


  • Anti-HIV Agents
  • Reverse Transcriptase Inhibitors
  • Tetrazoles